BioCentury
ARTICLE | Company News

sanofi receives option to Alopexx mAb

December 11, 2009 2:02 AM UTC

Alopexx Pharmaceuticals LLC (Cambridge, Mass.) granted sanofi-aventis Group (Euronext:SAN; NYSE:SNY) an option to license exclusive, worldwide rights to F598. The mAb against poly-N-acetyl glucosamine...